A132 THREE QUARTERS OF INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFLIXIMAB THERAPY IN CLINICAL REMISSION SHOW EVIDENCE OF MUCOSAL INFLAMMATION WITH ELEVATED FECAL CALPROTECTIN

Lignende værker

• Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
  af: Huang, Vivian W., et al.
  Udgivet: (2015)
• A147 COMBINING INFLIXIMAB TROUGH LEVELS AND FECAL CALPROTECTIN LEVELS WITH CLINICAL DATA HAS THE POTENTIAL TO GUIDE CLINICAL DECISION-MAKING IN IMPROVING OUTCOMES FOR INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFLIXIMAB.
  af: Amin, A, et al.
  Udgivet: (2018)
• A137 THERAPEUTIC DRUG MONITORING WITH INFLIXIMAB TROUGH LEVELS LEAD TO INCREASED INTERVENTION
  af: Stern, N C, et al.
  Udgivet: (2018)
• A84 HIGH FECAL CALPROTECTIN LEVELS IN ULCERATIVE COLITIS PATIENTS IN CLINICAL REMISSION ARE ASSOCIATED WITH SPECIFIC CLINICAL AND DIETARY INTAKE PARAMETERS.
  af: Keshteli, A H, et al.
  Udgivet: (2018)
• A142 INFLAMMATORY BOWEL DISEASE PATIENTS REQUIRE AN INCREASED ADALIMUMAB DRUG LEVEL TO SIMULTANEOUSLY ACHIEVE CLINICAL AND BIOLOGICAL REMISSION
  af: Cookson, T A, et al.
  Udgivet: (2019)